Birchview Capital, LP Cytokinetics Inc Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Birchview Capital, LP holds 10,000 shares of CYTK stock, worth $457,400. This represents 0.49% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$457,400
Previous $541,000
2.4%
% of portfolio
0.49%
Previous 0.54%
Shares
5 transactions
Others Institutions Holding CYTK
# of Institutions
407Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$671 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$538 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$443 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$356 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$295 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.31B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...